JTCS KCI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Menasche, P.
Right arrow Articles by Piwnica, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Menasche, P.
Right arrow Articles by Piwnica, A.

The Journal of Thoracic and Cardiovascular Surgery, Vol 96, 582-589, Copyright © 1988 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association


ARTICLES

Deferoxamine reduces neutrophil-mediated free radical production during cardiopulmonary bypass in man

P Menasche, C Pasquier, S Bellucci, P Lorente, P Jaillon and A Piwnica
Service de Chirurgie Cardio-Vasculaire, Hopital Lariboisiere, Paris, France.

We assessed the effects of the iron chelator deferoxamine in 24 adult patients (12 controls, 12 treated) undergoing cardiopulmonary bypass for various cardiac operations. Deferoxamine was given both intravenously (30 mg/kg of body weight, starting 30 minutes before and ending 30 minutes after bypass) and as an additive to the cardioplegic solution (250 mg/L). Right atrial blood samples were taken before, during, and after bypass, and isolated polymorphonuclear neutrophils were evaluated for their capacity to generate superoxide radicals after stimulation with N-formyl-methionyl-leucyl-phenylalanine (FLMP, 10(-7) mol) and phorbol myristate acetate (100 ng/ml). At the same sampling times, measurement of the plasma levels of 6-keto-prostaglandin F1 alpha, the stable derivative of prostacyclin, was used as an index of membrane phospholipid breakdown. The two groups were not significantly different with regard to age, duration of bypass, and quantitative changes in polymorphonuclear neutrophil counts during the operation. Before bypass, the superoxide production of FMLP-stimulated polymorphonuclear neutrophils was comparable in the two groups. Conversely, after bypass, polymorphonuclear neutrophils harvested from deferoxamine-treated patients produced significantly fewer superoxide radicals than those of control patients (1.9 +/- 0.3 versus 3.7 +/- 0.2 nmol/10(6) polymorphonuclear neutrophils per minute, p less than 0.05). Stimulation of polymorphonuclear neutrophils by phorbol myristate acetate yielded similar changes, as the postbypass superoxide production was 12.6 +/- 2.5 nmol/10(6)/min in control patients and 7.1 +/- 0.9 nmol/10(6)/min in those receiving deferoxamine (p less than 0.05). In contrast, plasma levels of 6-keto-prostaglandin F1 alpha were not significantly different between the two groups. We conclude that deferoxamine-exposed polymorphonuclear neutrophils have a decreased oxidative responsiveness, compatible with the fact that they may have been less "primed" by secretagogues released during bypass, as compared with cells of untreated patients. Our results are consistent with the hypothesis that deferoxamine, by inhibiting iron-catalyzed free radical production, may limit the free radical-mediated amplification of the inflammatory response to bypass and as such could be effective in reducing the harmful effects of extracorporeal circulation.


This article has been cited by other articles:


Home page
Asian Cardiovasc. Thorac. Ann.Home page
Y. Kadoi
Pharmacological Neuroprotection During Cardiac Surgery
Asian Cardiovasc Thorac Ann, April 1, 2007; 15(2): 167 - 177.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
I. A. Paraskevaidis, E. K. Iliodromitis, D. Vlahakos, D. P. Tsiapras, A. Nikolaidis, A. Marathias, A. Michalis, and D. Th. Kremastinos
Deferoxamine infusion during coronary artery bypass grafting ameliorates lipid peroxidation and protects the myocardium against reperfusion injury: immediate and long-term significance
Eur. Heart J., February 1, 2005; 26(3): 263 - 270.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
P. Tossios, W. Bloch, A. Huebner, M. R. Raji, F. Dodos, O. Klass, M. Suedkamp, S.-M. Kasper, M. Hellmich, and U. Mehlhorn
N-acetylcysteine prevents reactive oxygen species-mediated myocardial stress in patients undergoing cardiac surgery: Results of a randomized, double-blind, placebo-controlled clinical trial
J. Thorac. Cardiovasc. Surg., November 1, 2003; 126(5): 1513 - 1520.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
G. Valli and E.-G. V. Giardina
Benefits, adverse effects and drug interactionsof herbal therapies with cardiovascular effects
J. Am. Coll. Cardiol., April 3, 2002; 39(7): 1083 - 1095.
[Abstract] [Full Text] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
H. A. Hennein
Inflammation After Cardiopulmonary Bypass: Therapy for the Postpump Syndrome
Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2001; 5(3): 236 - 255.
[Abstract] [PDF]


Home page
Ann. Thorac. Surg.Home page
A. E. Vento, J. Aittomaki, K. A. Verkkala, L. J. Heikkila, J. A. Salo, J. Sipponen, and O. J. Ramo
Nitecapone as an additive to crystalloid cardioplegia in patients who had coronary artery bypass grafting
Ann. Thorac. Surg., August 1, 1999; 68(2): 413 - 420.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
T. Mihaljevic, M. Tonz, L. K. von Segesser, M. Pasic, P. Grob, J. Fehr, B. Seifert, and M. Turina
The influence of leukocyte filtration during cardiopulmonary bypass on postoperative lung function: A clinical study
J. Thorac. Cardiovasc. Surg., June 1, 1995; 109(6): 1138 - 1145.
[Abstract] [Full Text]


Home page
CirculationHome page
P. R. Hansen
Role of Neutrophils in Myocardial Ischemia and Reperfusion
Circulation, March 15, 1995; 91(6): 1872 - 1885.
[Abstract] [Full Text]


Home page
Ann. Thorac. Surg.Home page
G. Drossos, A. Lazou, P. Panagopoulos, and S. Westaby
Deferoxamine cardioplegia reduces superoxide radical production in human myocardium
Ann. Thorac. Surg., January 1, 1995; 59(1): 169 - 172.
[Abstract] [PDF]


Home page
PERSPECT VASC SURG ENDOVASC THERHome page
R. E. Kirschner and G. A. Fantini
Role of Iron in Reoxygenation Injury of Postischemic Skeletal Muscle
Perspectives in Vascular Surgery and Endovascular Therapy, January 1, 1992; 5(2): 69 - 83.
[PDF]


Home page
Ann. Thorac. Surg.Home page
P. Menasche and A. Piwnica
Free radicals and myocardial protection: A surgical viewpoint
Ann. Thorac. Surg., June 1, 1989; 47(6): 939 - 945.
[Abstract] [PDF]


Home page
PerfusionHome page
D. Royston
Interventions to reduce cerebral injury during cardiac surgery - the effect of physical and pharmacological agents
Perfusion, April 1, 1989; 4(2): 153 - 161.
[PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1988 by The American Association for Thoracic Surgery.